...targets from Helicon. Sapient will receive an undisclosed upfront payment and is eligible for milestones. Helicon Therapeutics Inc....

...Ventures as a senior advisor. Until 2005, he was Chairman and CEO of neurology company Helicon Therapeutics Inc....

...II testing to treat age-associated memory impairment. Helicon licensed the compound from Inflazyme in 2003. Helicon Therapeutics Inc....

...is in Phase I testing to treat inflammation. The PDE-4 program's IPL455,903 is partnered with Helicon Therapeutics Inc....

...IZP said it was told by partner Helicon that IPL455,903 failed to show significant effects on...
...of up to 90 mg. IZP expects to receive full data from Helicon this month. Helicon Therapeutics Inc....

...formerly adjunct associate professor at Cold Spring Harbor Laboratory and director of model systems at Helicon Therapeutics Inc. WIR...

...4-week, double-blind, placebo-controlled, European Phase IIa trial in about 75 patients with age-associated memory impairment. Helicon Therapeutics Inc....

...and well tolerated at all doses tested up to 135 mg daily for 14 days. Helicon Therapeutics Inc....

...acceptable pharmacokinetic profile. In particular, the companies noted that there was no evidence of emesis. Helicon Therapeutics Inc....

...PDE-4 ) inhibitor, is partnered with Helicon Therapeutics Inc. (Uniondale, N.Y.) and is in Phase I trials. Helicon...